Tumor Ablation Market Size, Share & Trends by Technology (Radiofrequency, Microwave, Laser, IRE, HIFU, Cryoablation), Product (Generators, Probes), Mode (Surgical, Laparoscopic, Percutaneous), Cancer (Liver, Lung, Bone), End User (Hospitals, Clinic) & Region - Global Forecast to 2029
The global tumor ablation market is projected to reach USD 1.4 billion by 2029 from USD 0.8 billion in 2024, at a CAGR of 10.0% from 2024 to 2029. Aging population, coupled with a rise in tumor cases such as osteoid osteoma, has increased the demand for these products. Moreover, increased awareness of ablation procedures over conventional procedures has driven demand for tumor ablation systems.
“The radiofrequency ablation segment of technology segment held the largest share of the market in 2023”
The tumor ablation market is segmented based on technology into radiofrequency ablation, microwave ablation, laser ablation, high-intensity focused ultrasound (HIFU), cryoablation, and irreversible electroporation (IRE). As the global population ages, conditions affecting the major organs are more prevalent, contributing to the demand for supportive and rehabilitative solutions. Additionally, advancements in technology have led to the development and incorporation of ablation systems, expanding the market further.
“The generators segment is projected to register the highest CAGR during the forecast period.”
Based on product type, the tumor ablation market is segmented into generators and probes/electrodes. The generators segment accounted for the largest market share in 2023. The probes/electrodes market is witnessing growth due to recent regulatory approvals of ablation systems and favourable reimbursement policies. The probes/electrodes have undergone certain technological advancements supporting the precise ablation procedure. The growing awareness of the importance of early detection and the shift towards value-based healthcare has also contributed to the increasing demand for soft and elastic braces and its growing market.
“The laparoscopic ablation segment for mode of treatment segment is projected to register a significant CAGR during the forecast period.”
Based on mode of treatment, the tumor ablation market is segmented into surgical ablation, laparoscopic ablation, and percutaneous ablation . The surgical ablation segment accounted for the largest market share in 2023. Growing investments in R&D and rising demand for less invasive alternative is driving the growth of this segment.
“The liver cancer segment for application segment held held the largest share of the market in 2022”.
Based on application, the tumor ablation market is segmented into liver cancer, lung cancer, bone cancer, kidney cancer, and other applications. The liver cancer was the major segment, accounted for the largest share of the tumor ablation market in 2023. Rising cancer incidence is supported by the increasing aging population. This ultimately drives the adoption of tumor ablation systems. A rising number of campaigns for the early detection of symptoms is also contributing to the increasing utilization of ablation treatment in end-user facilities.
“The cancer care center segment for the end user segment is projected to register a significant CAGR during the forecast period.”
The tumor ablation market is segmented by end user into hospitals and clinics, cancer care centers, and ambulatory surgery centers. The hospitals and clinics segment accounted for a significant market share in 2023. The emphasis on non- and minimally invasive treatment among the geriatric population helps the growing preference for ablation treatment solutions, driving the integration of tumor ablation systems into hospital settings.
“The market in the North America region is expected to witness the highest growth during the forecast period.”
The North America tumor ablation market is expected to hold a major share during the forecast period. The US market holds a dominating position in the North American market, primarily due to the region's high healthcare spending, rising prevalence of target diseases, a growing number of non-invasive treatments, and technological advancements in ablation systems.
A breakdown of the primary participants referred to for this report is provided below:
Research Coverage
This report studies the tumor ablation market based on technology, product type, mode of treatment, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall tumor ablation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
“The radiofrequency ablation segment of technology segment held the largest share of the market in 2023”
The tumor ablation market is segmented based on technology into radiofrequency ablation, microwave ablation, laser ablation, high-intensity focused ultrasound (HIFU), cryoablation, and irreversible electroporation (IRE). As the global population ages, conditions affecting the major organs are more prevalent, contributing to the demand for supportive and rehabilitative solutions. Additionally, advancements in technology have led to the development and incorporation of ablation systems, expanding the market further.
“The generators segment is projected to register the highest CAGR during the forecast period.”
Based on product type, the tumor ablation market is segmented into generators and probes/electrodes. The generators segment accounted for the largest market share in 2023. The probes/electrodes market is witnessing growth due to recent regulatory approvals of ablation systems and favourable reimbursement policies. The probes/electrodes have undergone certain technological advancements supporting the precise ablation procedure. The growing awareness of the importance of early detection and the shift towards value-based healthcare has also contributed to the increasing demand for soft and elastic braces and its growing market.
“The laparoscopic ablation segment for mode of treatment segment is projected to register a significant CAGR during the forecast period.”
Based on mode of treatment, the tumor ablation market is segmented into surgical ablation, laparoscopic ablation, and percutaneous ablation . The surgical ablation segment accounted for the largest market share in 2023. Growing investments in R&D and rising demand for less invasive alternative is driving the growth of this segment.
“The liver cancer segment for application segment held held the largest share of the market in 2022”.
Based on application, the tumor ablation market is segmented into liver cancer, lung cancer, bone cancer, kidney cancer, and other applications. The liver cancer was the major segment, accounted for the largest share of the tumor ablation market in 2023. Rising cancer incidence is supported by the increasing aging population. This ultimately drives the adoption of tumor ablation systems. A rising number of campaigns for the early detection of symptoms is also contributing to the increasing utilization of ablation treatment in end-user facilities.
“The cancer care center segment for the end user segment is projected to register a significant CAGR during the forecast period.”
The tumor ablation market is segmented by end user into hospitals and clinics, cancer care centers, and ambulatory surgery centers. The hospitals and clinics segment accounted for a significant market share in 2023. The emphasis on non- and minimally invasive treatment among the geriatric population helps the growing preference for ablation treatment solutions, driving the integration of tumor ablation systems into hospital settings.
“The market in the North America region is expected to witness the highest growth during the forecast period.”
The North America tumor ablation market is expected to hold a major share during the forecast period. The US market holds a dominating position in the North American market, primarily due to the region's high healthcare spending, rising prevalence of target diseases, a growing number of non-invasive treatments, and technological advancements in ablation systems.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–30%, Tier 2–42%, and Tier 3– 28%
- By Designation: Director-level–10%, C-level–14%, and Others–76%
- By Region: North America–40%, Europe–30%, Asia Pacific–22%, Latin America–6%, and the Middle East & Africa–2%
Research Coverage
This report studies the tumor ablation market based on technology, product type, mode of treatment, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall tumor ablation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
- Analysis of key drivers (increasing cancer incidence and rising geriatric population, rising focus on minimally invasive procedures, technological advancements in the field of tumor ablation, rising number of awareness campaigns and early detection), restraints (high cost of tumor ablation systems, unfavorable reimbursement scenario), opportunities (rising healthcare expenditure across emerging countries, increasing number of hospitals), and challenges (rising adoption of refurbished tumor ablation systems, hospital budget cuts) influencing the growth of the tumor ablation market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the tumor ablation market
- Market Development: Comprehensive information about lucrative markets–the report analyses the tumor ablation market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tumor ablation market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players – such as Johnson & Johnson (US), Medtronic Plc (Ireland), Stryker Corporation (US), Varian Medical Systems, Inc. (US), Olympus (Japan), AngioDynamics, Inc. (US), Boston Scientific Corporation (US) among others.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 KEY STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 TUMOR ABLATION MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
2.2.1.2 Approach 2: Customer-based market estimation
FIGURE 6 TUMOR ABLATION MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
2.3 DATA VALIDATION APPROACH
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ASSESSMENT
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RISK ASSESSMENT
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 9 TUMOR ABLATION MARKET, TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 10 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 11 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2024 VS. 2029 (USD MILLION)
FIGURE 12 TUMOR ABLATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 13 TUMOR ABLATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 14 TUMOR ABLATION MARKET: GEOGRAPHIC SNAPSHOT
4 PREMIUM INSIGHTS
4.1 TUMOR ABLATION MARKET OVERVIEW
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY
FIGURE 16 MICROWAVE ABLATION SEGMENT TO REGISTER SIGNIFICANT GROWTH IN NORTH AMERICA DURING FORECAST PERIOD
4.3 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION
FIGURE 17 LIVER CANCER SEGMENT TO DOMINATE MARKET IN EUROPE DURING FORECAST PERIOD
4.4 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER
FIGURE 18 HOSPITALS & CLINICS SEGMENT TO CONTINUE TO HOLD LARGEST SHARE IN ASIA PACIFIC MARKET
4.5 GEOGRAPHIC SNAPSHOT OF TUMOR ABLATION MARKET
FIGURE 19 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 TUMOR ABLATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing cancer incidence and rising geriatric population
5.2.1.2 Rising focus on minimally invasive procedures
5.2.1.3 Technological advancements in field of tumor ablation
5.2.1.4 Rising number of awareness campaigns and early detection
5.2.2 RESTRAINTS
5.2.2.1 High cost of tumor ablation systems
5.2.2.2 Unfavorable regulatory scenario
5.2.3 OPPORTUNITIES
5.2.3.1 Rising healthcare expenditure across emerging economies
5.2.3.2 Increasing number of hospitals
5.2.4 CHALLENGES
5.2.4.1 Rising adoption of refurbished tumor ablation systems
5.2.4.2 Hospital budget cuts
5.3 REGULATORY ANALYSIS
5.3.1 KEY REGULATORY BODIES AND GOVERNMENT AGENCIES
TABLE 1 NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
TABLE 2 EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
TABLE 3 ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
TABLE 4 LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
TABLE 5 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
5.3.2 KEY REGULATORY GUIDELINES
5.3.2.1 US
TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 7 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
FIGURE 21 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES
5.3.2.2 Canada
TABLE 8 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
FIGURE 22 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
5.3.2.3 Europe
FIGURE 23 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES
5.3.2.4 Asia Pacific
5.3.2.4.1 Japan
TABLE 9 JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES
TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
5.3.2.4.2 China
TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.3.2.4.3 India
TABLE 12 INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES
5.3.2.5 Latin America
5.3.2.5.1 Brazil
5.4 REIMBURSEMENT SCENARIO
TABLE 13 MEDICAL REIMBURSEMENT CPT CODES FOR MICROWAVE AND RADIOFREQUENCY ABLATION PROCEDURES IN US (EFFECTIVE JANUARY 1, 2022)
5.5 VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & DEVELOPMENT
5.5.2 MANUFACTURING & ASSEMBLY
5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
FIGURE 24 TUMOR ABLATION MARKET: VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 25 TUMOR ABLATION MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 26 TUMOR ABLATION MARKET: ECOSYSTEM ANALYSIS
TABLE 14 TUMOR ABLATION MARKET: ROLE IN ECOSYSTEM
5.8 INVESTMENT & FUNDING SCENARIO
FIGURE 27 NUMBER OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022
FIGURE 28 VALUE OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION)
5.9 PRICING ANALYSIS
FIGURE 29 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY TECHNOLOGY
FIGURE 30 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY REGION
TABLE 15 AVERAGE SELLING PRICE OF TUMOR ABLATION SYSTEMS, BY REGION, 2021–2023
5.10 TRADE ANALYSIS
TABLE 16 IMPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 17 EXPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2018–2022 (USD THOUSAND)
5.11 PATENT ANALYSIS
FIGURE 31 PATENT DETAILS FOR TUMOR ABLATION MARKET (JANUARY 2013– DECEMBER 2023)
5.12 PORTER’S FIVE FORCE ANALYSIS
TABLE 18 PORTER’S FIVE FORCES ANALYSIS: TUMOR ABLATION MARKET
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY CONFERENCES & EVENTS IN 2024–2025
TABLE 19 LIST OF MAJOR CONFERENCES & EVENTS IN TUMOR ABLATION MARKET, 2024–2025
5.14 CASE STUDY ANALYSIS
TABLE 20 CASE STUDY 1: RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY
TABLE 21 CASE STUDY 2: ABLATION OF LOCALIZED RENAL TUMOR
5.15 TECHNOLOGY ANALYSIS
5.15.1 KEY TECHNOLOGIES
5.15.1.1 Radiofrequency ablation and microwave ablation
5.15.1.2 Cryoablation
5.15.2 COMPLEMENTARY TECHNOLOGIES
5.15.2.1 Laparoscopy
5.15.2.2 Diagnostic imaging
5.15.3 ADJACENT TECHNOLOGIES
5.15.3.1 Electrosurgery
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 32 REVENUE SHIFT IN TUMOR ABLATION MARKET
5.17 KEY STAKEHOLDERS & BUYING CRITERIA
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
5.17.2 BUYING CRITERIA
FIGURE 34 KEY BUYING CRITERIA FOR PROCESS TUMOR ABLATION SYSTEMS
TABLE 23 KEY BUYING CRITERIA FOR TUMOR ABLATION SYSTEMS
5.18 UNMET NEEDS & KEY PAIN POINTS
TABLE 24 TUMOR ABLATION MARKET: CURRENT UNMET NEEDS
6 TUMOR ABLATION MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
TABLE 25 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
6.2 RADIOFREQUENCY ABLATION
6.2.1 LOW COST OF RADIOFREQUENCY ABLATION TO CONTRIBUTE TO MARKET GROWTH
TABLE 26 RADIOFREQUENCY ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3 MICROWAVE ABLATION
6.3.1 ADVANTAGES OF MICROWAVE ABLATION TO BOOST MARKET GROWTH
TABLE 27 MICROWAVE ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4 CRYOABLATION
6.4.1 HIGH SAFETY AND EFFICACY OF CRYOABLATION TO BOOST MARKET
TABLE 28 CRYOABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5 HIGH-INTENSITY-FOCUSED ULTRASOUND (HIFU)
6.5.1 TECHNOLOGICAL ADVANCEMENTS IN ULTRASOUND ABLATION TO FAVOR MARKET GROWTH
TABLE 29 HIGH-INTENSITY-FOCUSED ULTRASOUND MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6 OTHER TECHNOLOGIES
TABLE 30 OTHER TUMOR ABLATION TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
7 TUMOR ABLATION MARKET, BY PRODUCT TYPE
7.1 INTRODUCTION
TABLE 31 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 32 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (UNITS)
7.2 GENERATORS
7.2.1 RISING ADOPTION OF TUMOR ABLATION SYSTEMS TO PROPEL MARKET GROWTH
TABLE 33 TUMOR ABLATION GENERATORS MARKET, BY REGION, 2022–2029 (USD MILLION)
7.3 PROBES/ELECTRODES
7.3.1 RADIOFREQUENCY ABLATION PROBES
7.3.1.1 Rising adoption of radiofrequency ablation systems for multiple applications to propel market growth
TABLE 34 RADIOFREQUENCY ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
7.3.2 MICROWAVE ABLATION PROBES
7.3.2.1 Increasing cancer prevalence and precise ablation to boost adoption
TABLE 35 MICROWAVE ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
7.3.3 OTHER PROBES/ELECTRODES
TABLE 36 OTHER TUMOR ABLATION PROBES/ELECTRODES MARKET, BY REGION, 2022–2029 (USD MILLION)
8 TUMOR ABLATION MARKET, BY MODE OF TREATMENT
8.1 INTRODUCTION
TABLE 37 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
8.2 SURGICAL ABLATION
8.2.1 RISING UTILIZATION OF SURGICAL ABLATION IN END-USER FACILITIES TO PROPEL MARKET
TABLE 38 TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2022–2029 (USD MILLION)
8.3 LAPAROSCOPIC ABLATION
8.3.1 IMPROVED SUCCESS RATE AND REAL-TIME VISUALIZATION TO BOOST DEMAND
TABLE 39 TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY REGION, 2022–2029 (USD MILLION)
8.4 PERCUTANEOUS ABLATION
8.4.1 SHORTER RECOVERY TIME AND COST-EFFECTIVENESS OF PROCEDURE TO DRIVE SEGMENT
TABLE 40 TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY REGION, 2022–2029 (USD MILLION)
9 TUMOR ABLATION MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 41 TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
9.2 LIVER CANCER
9.2.1 PROMISING OUTCOMES OF ABLATION IN TREATING HCC TO DRIVE MARKET
TABLE 42 TUMOR ABLATION MARKET FOR LIVER CANCER, BY REGION, 2022–2029 (USD MILLION)
9.3 LUNG CANCER
9.3.1 RISING INCIDENCE OF LUNG CANCER TO FUEL MARKET
TABLE 43 TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)
9.4 KIDNEY CANCER
9.4.1 RISING PREVALENCE OF KIDNEY CANCER AND MINIMAL DAMAGE OF HEALTHY TISSUE TO DRIVE ADOPTION
TABLE 44 TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY REGION, 2022–2029 (USD MILLION)
9.5 BONE CANCER
9.5.1 RISING USE OF ABLATION TECHNIQUES TO TREAT OSTEOID OSTEOMA TO BOOST GROWTH
TABLE 45 TUMOR ABLATION MARKET FOR BONE CANCER, BY REGION, 2022–2029 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 46 TUMOR ABLATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
10 TUMOR ABLATION MARKET, BY END USER
10.1 INTRODUCTION
TABLE 47 TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2 HOSPITALS & CLINICS
10.2.1 INCREASING ADOPTION OF ADVANCED TUMOR ABLATION SYSTEMS TO PROPEL MARKET
TABLE 48 TUMOR ABLATION MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
10.3 CANCER CARE CENTERS
10.3.1 GROWING ESTABLISHMENT OF CANCER CARE CENTERS TO FUEL MARKET
TABLE 49 TUMOR ABLATION MARKET FOR CANCER CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
10.4 OTHER END USERS
TABLE 50 TUMOR ABLATION MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
11 TUMOR ABLATION MARKET, BY REGION
11.1 INTRODUCTION
TABLE 51 TUMOR ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 35 NORTH AMERICA: TUMOR ABLATION MARKET SNAPSHOT
TABLE 52 NORTH AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 53 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 54 NORTH AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 55 NORTH AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
TABLE 56 NORTH AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 57 NORTH AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Rising prevalence of cancer to propel market growth
TABLE 58 US: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Growing burden of cancer to support market growth
TABLE 59 CANADA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3 EUROPE
TABLE 60 EUROPE: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 61 EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 62 EUROPE: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 63 EUROPE: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
TABLE 64 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 65 EUROPE: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Highly developed healthcare infrastructure and rising disease incidence to ensure strong growth prospects
TABLE 66 GERMANY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Growing geriatric population to support market growth in France
TABLE 67 FRANCE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3.4 UK
11.3.4.1 Growing target patient population to support market growth in UK
TABLE 68 UK: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Rising awareness to support market growth
TABLE 69 ITALY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Increasing government funding for research to support market growth
TABLE 70 SPAIN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 71 REST OF EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 36 ASIA PACIFIC: TUMOR ABLATION MARKET SNAPSHOT
TABLE 72 ASIA PACIFIC: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 74 ASIA PACIFIC: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 75 ASIA PACIFIC: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
TABLE 76 ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 77 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 JAPAN
11.4.2.1 Presence of universal healthcare reimbursement scenario to drive market growth
TABLE 78 JAPAN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4.3 CHINA
11.4.3.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth
TABLE 79 CHINA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Ongoing modernization and infrastructure development in India to support market growth
TABLE 80 INDIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Rising research investments and awareness campaigns to support market growth
TABLE 81 AUSTRALIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4.6 SOUTH KOREA
11.4.6.1 Rising R&D and promising clinical trials to positively impact market growth
TABLE 82 SOUTH KOREA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 83 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 84 LATIN AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 86 LATIN AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 87 LATIN AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
TABLE 88 LATIN AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 89 LATIN AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.2 BRAZIL
11.5.2.1 Modernization of healthcare facilities in Brazil to boost market
TABLE 90 BRAZIL: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Availability of advanced care and increasing awareness programs to fuel market growth in Mexico
TABLE 91 MEXICO: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 92 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH
TABLE 93 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 94 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 95 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
TABLE 96 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 97 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN TUMOR ABLATION MARKET
TABLE 98 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
12.3 REVENUE ANALYSIS
FIGURE 37 REVENUE ANALYSIS OF TOP THREE PLAYERS IN TUMOR ABLATION MARKET (2021–2023)
12.4 MARKET SHARE ANALYSIS
FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 99 TUMOR ABLATION TECHNOLOGY MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 39 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
FIGURE 40 TUMOR ABLATION MARKET: COMPANY FOOTPRINT
12.5.5.2 Technology footprint
TABLE 100 TUMOR ABLATION MARKET: TECHNOLOGY FOOTPRINT
12.5.5.3 Region footprint
TABLE 101 TUMOR ABLATION MARKET: REGION FOOTPRINT
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 41 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
TABLE 102 TUMOR ABLATION MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 103 TUMOR ABLATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
12.7 COMPANY VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
FIGURE 42 EV/EBITDA OF KEY VENDORS
12.7.2 COMPANY VALUATION
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
12.8 BRAND/PRODUCT COMPARISON
FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES/APPROVALS
TABLE 104 TUMOR ABLATION MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2024
12.9.2 DEALS
TABLE 105 TUMOR ABLATION MARKET: DEALS, JANUARY 2021–MARCH 2024
12.9.3 EXPANSIONS
TABLE 106 TUMOR ABLATION MARKET: EXPANSIONS, JANUARY 2021–MARCH 2024
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats)*
13.1.1 MEDTRONIC PLC
TABLE 107 MEDTRONIC PLC: COMPANY OVERVIEW
FIGURE 45 MEDTRONIC PLC: COMPANY SNAPSHOT (2023)
TABLE 108 MEDTRONIC PLC: PRODUCTS OFFERED
TABLE 109 MEDTRONIC PLC: PRODUCT APPROVALS
13.1.2 JOHNSON & JOHNSON MEDTECH (ETHICON)
TABLE 110 JOHNSON & JOHNSON MEDTECH: COMPANY OVERVIEW
FIGURE 46 JOHNSON & JOHNSON MEDTECH: COMPANY SNAPSHOT (2022)
TABLE 111 JOHNSON & JOHNSON MEDTECH: PRODUCTS OFFERED
13.1.3 STRYKER CORPORATION
TABLE 112 STRYKER CORPORATION: COMPANY OVERVIEW
FIGURE 47 STRYKER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 113 STRYKER CORPORATION: PRODUCTS OFFERED
TABLE 114 STRYKER CORPORATION: PRODUCT APPROVALS
TABLE 115 STRYKER CORPORATION: EXPANSIONS
13.1.4 VARIAN MEDICAL SYSTEMS, INC.
TABLE 116 VARIAN MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW
FIGURE 48 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2023)
TABLE 117 VARIAN MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED
TABLE 118 VARIAN MEDICAL SYSTEMS, INC.: PRODUCT LAUNCHES
TABLE 119 VARIAN MEDICAL SYSTEMS, INC.: DEALS
13.1.5 ANGIODYNAMICS, INC.
TABLE 120 ANGIODYNAMICS, INC.: COMPANY OVERVIEW
FIGURE 49 ANGIODYNAMICS, INC.: COMPANY SNAPSHOT (2023)
TABLE 121 ANGIODYNAMICS, INC.: PRODUCTS OFFERED
TABLE 122 ANGIODYNAMICS, INC.: DEALS
13.1.6 BOSTON SCIENTIFIC CORPORATION
TABLE 123 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
FIGURE 50 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 124 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
13.1.7 EDAP TMS S.A.
TABLE 125 EDAP TMS S.A.: COMPANY OVERVIEW
FIGURE 51 EDAP TMS S.A.: COMPANY SNAPSHOT (2023)
TABLE 126 EDAP TMS S.A.: PRODUCTS OFFERED
13.1.8 MERMAID MEDICAL
TABLE 127 MERMAID MEDICAL: COMPANY OVERVIEW
TABLE 128 MERMAID MEDICAL: PRODUCTS OFFERED
13.1.9 CANYON MEDICAL INC.
TABLE 129 CANYON MEDICAL INC.: COMPANY OVERVIEW
TABLE 130 CANYON MEDICAL INC.: PRODUCTS OFFERED
13.1.10 OLYMPUS CORPORATION
TABLE 131 OLYMPUS CORPORATION: COMPANY OVERVIEW
FIGURE 52 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 132 OLYMPUS CORPORATION: PRODUCTS OFFERED
TABLE 133 OLYMPUS CORPORATION: PRODUCT LAUNCHES
13.1.11 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.
TABLE 134 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
TABLE 135 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
13.1.12 MERIT MEDICAL SYSTEMS, INC.
TABLE 136 MERIT MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW
FIGURE 53 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022)
TABLE 137 MERIT MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED
13.1.13 BIOVENTUS INC.
TABLE 138 BIOVENTUS INC.: COMPANY OVERVIEW
FIGURE 54 BIOVENTUS INC.: COMPANY SNAPSHOT (2023)
TABLE 139 BIOVENTUS INC.: PRODUCTS OFFERED
TABLE 140 BIOVENTUS INC.: DEALS
13.1.14 ICECURE MEDICAL LTD.
TABLE 141 ICECURE MEDICAL LTD.: COMPANY OVERVIEW
FIGURE 55 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023)
TABLE 142 ICECURE MEDICAL LTD.: PRODUCTS OFFERED
TABLE 143 ICECURE MEDICAL LTD.: PRODUCT APPROVALS
TABLE 144 ICECURE MEDICAL LTD.: DEALS
13.1.15 CONMED CORPORATION
TABLE 145 CONMED CORPORATION: COMPANY OVERVIEW
FIGURE 56 CONMED CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 146 CONMED CORPORATION: PRODUCTS OFFERED
13.2 OTHER PLAYERS
13.2.1 MONTERIS MEDICAL
13.2.2 MIANYANG SONIC ELECTRONIC
13.2.3 RF MEDICAL
13.2.4 MINIMAX MEDICAL HOLDING GROUP
13.2.5 SONABLATE
13.2.6 ECO MEDICAL TECHNOLOGY (NANJING) CO., LTD.
13.2.7 STARMED CO., LTD.
13.2.8 SURGNOVA
13.2.9 CREO MEDICAL
13.2.10 MEDSPHERE SHANGHAI
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 KEY STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 TUMOR ABLATION MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
2.2.1.2 Approach 2: Customer-based market estimation
FIGURE 6 TUMOR ABLATION MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
2.3 DATA VALIDATION APPROACH
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ASSESSMENT
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RISK ASSESSMENT
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 9 TUMOR ABLATION MARKET, TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 10 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 11 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2024 VS. 2029 (USD MILLION)
FIGURE 12 TUMOR ABLATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 13 TUMOR ABLATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 14 TUMOR ABLATION MARKET: GEOGRAPHIC SNAPSHOT
4 PREMIUM INSIGHTS
4.1 TUMOR ABLATION MARKET OVERVIEW
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY
FIGURE 16 MICROWAVE ABLATION SEGMENT TO REGISTER SIGNIFICANT GROWTH IN NORTH AMERICA DURING FORECAST PERIOD
4.3 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION
FIGURE 17 LIVER CANCER SEGMENT TO DOMINATE MARKET IN EUROPE DURING FORECAST PERIOD
4.4 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER
FIGURE 18 HOSPITALS & CLINICS SEGMENT TO CONTINUE TO HOLD LARGEST SHARE IN ASIA PACIFIC MARKET
4.5 GEOGRAPHIC SNAPSHOT OF TUMOR ABLATION MARKET
FIGURE 19 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 TUMOR ABLATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing cancer incidence and rising geriatric population
5.2.1.2 Rising focus on minimally invasive procedures
5.2.1.3 Technological advancements in field of tumor ablation
5.2.1.4 Rising number of awareness campaigns and early detection
5.2.2 RESTRAINTS
5.2.2.1 High cost of tumor ablation systems
5.2.2.2 Unfavorable regulatory scenario
5.2.3 OPPORTUNITIES
5.2.3.1 Rising healthcare expenditure across emerging economies
5.2.3.2 Increasing number of hospitals
5.2.4 CHALLENGES
5.2.4.1 Rising adoption of refurbished tumor ablation systems
5.2.4.2 Hospital budget cuts
5.3 REGULATORY ANALYSIS
5.3.1 KEY REGULATORY BODIES AND GOVERNMENT AGENCIES
TABLE 1 NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
TABLE 2 EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
TABLE 3 ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
TABLE 4 LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
TABLE 5 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
5.3.2 KEY REGULATORY GUIDELINES
5.3.2.1 US
TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 7 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
FIGURE 21 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES
5.3.2.2 Canada
TABLE 8 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
FIGURE 22 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
5.3.2.3 Europe
FIGURE 23 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES
5.3.2.4 Asia Pacific
5.3.2.4.1 Japan
TABLE 9 JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES
TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
5.3.2.4.2 China
TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.3.2.4.3 India
TABLE 12 INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES
5.3.2.5 Latin America
5.3.2.5.1 Brazil
5.4 REIMBURSEMENT SCENARIO
TABLE 13 MEDICAL REIMBURSEMENT CPT CODES FOR MICROWAVE AND RADIOFREQUENCY ABLATION PROCEDURES IN US (EFFECTIVE JANUARY 1, 2022)
5.5 VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & DEVELOPMENT
5.5.2 MANUFACTURING & ASSEMBLY
5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
FIGURE 24 TUMOR ABLATION MARKET: VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 25 TUMOR ABLATION MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 26 TUMOR ABLATION MARKET: ECOSYSTEM ANALYSIS
TABLE 14 TUMOR ABLATION MARKET: ROLE IN ECOSYSTEM
5.8 INVESTMENT & FUNDING SCENARIO
FIGURE 27 NUMBER OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022
FIGURE 28 VALUE OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION)
5.9 PRICING ANALYSIS
FIGURE 29 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY TECHNOLOGY
FIGURE 30 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY REGION
TABLE 15 AVERAGE SELLING PRICE OF TUMOR ABLATION SYSTEMS, BY REGION, 2021–2023
5.10 TRADE ANALYSIS
TABLE 16 IMPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 17 EXPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2018–2022 (USD THOUSAND)
5.11 PATENT ANALYSIS
FIGURE 31 PATENT DETAILS FOR TUMOR ABLATION MARKET (JANUARY 2013– DECEMBER 2023)
5.12 PORTER’S FIVE FORCE ANALYSIS
TABLE 18 PORTER’S FIVE FORCES ANALYSIS: TUMOR ABLATION MARKET
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY CONFERENCES & EVENTS IN 2024–2025
TABLE 19 LIST OF MAJOR CONFERENCES & EVENTS IN TUMOR ABLATION MARKET, 2024–2025
5.14 CASE STUDY ANALYSIS
TABLE 20 CASE STUDY 1: RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY
TABLE 21 CASE STUDY 2: ABLATION OF LOCALIZED RENAL TUMOR
5.15 TECHNOLOGY ANALYSIS
5.15.1 KEY TECHNOLOGIES
5.15.1.1 Radiofrequency ablation and microwave ablation
5.15.1.2 Cryoablation
5.15.2 COMPLEMENTARY TECHNOLOGIES
5.15.2.1 Laparoscopy
5.15.2.2 Diagnostic imaging
5.15.3 ADJACENT TECHNOLOGIES
5.15.3.1 Electrosurgery
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 32 REVENUE SHIFT IN TUMOR ABLATION MARKET
5.17 KEY STAKEHOLDERS & BUYING CRITERIA
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
5.17.2 BUYING CRITERIA
FIGURE 34 KEY BUYING CRITERIA FOR PROCESS TUMOR ABLATION SYSTEMS
TABLE 23 KEY BUYING CRITERIA FOR TUMOR ABLATION SYSTEMS
5.18 UNMET NEEDS & KEY PAIN POINTS
TABLE 24 TUMOR ABLATION MARKET: CURRENT UNMET NEEDS
6 TUMOR ABLATION MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
TABLE 25 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
6.2 RADIOFREQUENCY ABLATION
6.2.1 LOW COST OF RADIOFREQUENCY ABLATION TO CONTRIBUTE TO MARKET GROWTH
TABLE 26 RADIOFREQUENCY ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3 MICROWAVE ABLATION
6.3.1 ADVANTAGES OF MICROWAVE ABLATION TO BOOST MARKET GROWTH
TABLE 27 MICROWAVE ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.4 CRYOABLATION
6.4.1 HIGH SAFETY AND EFFICACY OF CRYOABLATION TO BOOST MARKET
TABLE 28 CRYOABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.5 HIGH-INTENSITY-FOCUSED ULTRASOUND (HIFU)
6.5.1 TECHNOLOGICAL ADVANCEMENTS IN ULTRASOUND ABLATION TO FAVOR MARKET GROWTH
TABLE 29 HIGH-INTENSITY-FOCUSED ULTRASOUND MARKET, BY REGION, 2022–2029 (USD MILLION)
6.6 OTHER TECHNOLOGIES
TABLE 30 OTHER TUMOR ABLATION TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
7 TUMOR ABLATION MARKET, BY PRODUCT TYPE
7.1 INTRODUCTION
TABLE 31 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 32 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (UNITS)
7.2 GENERATORS
7.2.1 RISING ADOPTION OF TUMOR ABLATION SYSTEMS TO PROPEL MARKET GROWTH
TABLE 33 TUMOR ABLATION GENERATORS MARKET, BY REGION, 2022–2029 (USD MILLION)
7.3 PROBES/ELECTRODES
7.3.1 RADIOFREQUENCY ABLATION PROBES
7.3.1.1 Rising adoption of radiofrequency ablation systems for multiple applications to propel market growth
TABLE 34 RADIOFREQUENCY ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
7.3.2 MICROWAVE ABLATION PROBES
7.3.2.1 Increasing cancer prevalence and precise ablation to boost adoption
TABLE 35 MICROWAVE ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
7.3.3 OTHER PROBES/ELECTRODES
TABLE 36 OTHER TUMOR ABLATION PROBES/ELECTRODES MARKET, BY REGION, 2022–2029 (USD MILLION)
8 TUMOR ABLATION MARKET, BY MODE OF TREATMENT
8.1 INTRODUCTION
TABLE 37 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
8.2 SURGICAL ABLATION
8.2.1 RISING UTILIZATION OF SURGICAL ABLATION IN END-USER FACILITIES TO PROPEL MARKET
TABLE 38 TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2022–2029 (USD MILLION)
8.3 LAPAROSCOPIC ABLATION
8.3.1 IMPROVED SUCCESS RATE AND REAL-TIME VISUALIZATION TO BOOST DEMAND
TABLE 39 TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY REGION, 2022–2029 (USD MILLION)
8.4 PERCUTANEOUS ABLATION
8.4.1 SHORTER RECOVERY TIME AND COST-EFFECTIVENESS OF PROCEDURE TO DRIVE SEGMENT
TABLE 40 TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY REGION, 2022–2029 (USD MILLION)
9 TUMOR ABLATION MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 41 TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
9.2 LIVER CANCER
9.2.1 PROMISING OUTCOMES OF ABLATION IN TREATING HCC TO DRIVE MARKET
TABLE 42 TUMOR ABLATION MARKET FOR LIVER CANCER, BY REGION, 2022–2029 (USD MILLION)
9.3 LUNG CANCER
9.3.1 RISING INCIDENCE OF LUNG CANCER TO FUEL MARKET
TABLE 43 TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)
9.4 KIDNEY CANCER
9.4.1 RISING PREVALENCE OF KIDNEY CANCER AND MINIMAL DAMAGE OF HEALTHY TISSUE TO DRIVE ADOPTION
TABLE 44 TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY REGION, 2022–2029 (USD MILLION)
9.5 BONE CANCER
9.5.1 RISING USE OF ABLATION TECHNIQUES TO TREAT OSTEOID OSTEOMA TO BOOST GROWTH
TABLE 45 TUMOR ABLATION MARKET FOR BONE CANCER, BY REGION, 2022–2029 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 46 TUMOR ABLATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
10 TUMOR ABLATION MARKET, BY END USER
10.1 INTRODUCTION
TABLE 47 TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2 HOSPITALS & CLINICS
10.2.1 INCREASING ADOPTION OF ADVANCED TUMOR ABLATION SYSTEMS TO PROPEL MARKET
TABLE 48 TUMOR ABLATION MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
10.3 CANCER CARE CENTERS
10.3.1 GROWING ESTABLISHMENT OF CANCER CARE CENTERS TO FUEL MARKET
TABLE 49 TUMOR ABLATION MARKET FOR CANCER CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
10.4 OTHER END USERS
TABLE 50 TUMOR ABLATION MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
11 TUMOR ABLATION MARKET, BY REGION
11.1 INTRODUCTION
TABLE 51 TUMOR ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 35 NORTH AMERICA: TUMOR ABLATION MARKET SNAPSHOT
TABLE 52 NORTH AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 53 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 54 NORTH AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 55 NORTH AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
TABLE 56 NORTH AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 57 NORTH AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Rising prevalence of cancer to propel market growth
TABLE 58 US: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Growing burden of cancer to support market growth
TABLE 59 CANADA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3 EUROPE
TABLE 60 EUROPE: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 61 EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 62 EUROPE: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 63 EUROPE: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
TABLE 64 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 65 EUROPE: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Highly developed healthcare infrastructure and rising disease incidence to ensure strong growth prospects
TABLE 66 GERMANY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Growing geriatric population to support market growth in France
TABLE 67 FRANCE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3.4 UK
11.3.4.1 Growing target patient population to support market growth in UK
TABLE 68 UK: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Rising awareness to support market growth
TABLE 69 ITALY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Increasing government funding for research to support market growth
TABLE 70 SPAIN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 71 REST OF EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 36 ASIA PACIFIC: TUMOR ABLATION MARKET SNAPSHOT
TABLE 72 ASIA PACIFIC: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 74 ASIA PACIFIC: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 75 ASIA PACIFIC: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
TABLE 76 ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 77 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 JAPAN
11.4.2.1 Presence of universal healthcare reimbursement scenario to drive market growth
TABLE 78 JAPAN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4.3 CHINA
11.4.3.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth
TABLE 79 CHINA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Ongoing modernization and infrastructure development in India to support market growth
TABLE 80 INDIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Rising research investments and awareness campaigns to support market growth
TABLE 81 AUSTRALIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4.6 SOUTH KOREA
11.4.6.1 Rising R&D and promising clinical trials to positively impact market growth
TABLE 82 SOUTH KOREA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 83 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 84 LATIN AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 86 LATIN AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 87 LATIN AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
TABLE 88 LATIN AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 89 LATIN AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.2 BRAZIL
11.5.2.1 Modernization of healthcare facilities in Brazil to boost market
TABLE 90 BRAZIL: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Availability of advanced care and increasing awareness programs to fuel market growth in Mexico
TABLE 91 MEXICO: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 92 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH
TABLE 93 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 94 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 95 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
TABLE 96 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 97 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN TUMOR ABLATION MARKET
TABLE 98 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
12.3 REVENUE ANALYSIS
FIGURE 37 REVENUE ANALYSIS OF TOP THREE PLAYERS IN TUMOR ABLATION MARKET (2021–2023)
12.4 MARKET SHARE ANALYSIS
FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 99 TUMOR ABLATION TECHNOLOGY MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 39 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
FIGURE 40 TUMOR ABLATION MARKET: COMPANY FOOTPRINT
12.5.5.2 Technology footprint
TABLE 100 TUMOR ABLATION MARKET: TECHNOLOGY FOOTPRINT
12.5.5.3 Region footprint
TABLE 101 TUMOR ABLATION MARKET: REGION FOOTPRINT
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 41 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
TABLE 102 TUMOR ABLATION MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 103 TUMOR ABLATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
12.7 COMPANY VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
FIGURE 42 EV/EBITDA OF KEY VENDORS
12.7.2 COMPANY VALUATION
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
12.8 BRAND/PRODUCT COMPARISON
FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES/APPROVALS
TABLE 104 TUMOR ABLATION MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2024
12.9.2 DEALS
TABLE 105 TUMOR ABLATION MARKET: DEALS, JANUARY 2021–MARCH 2024
12.9.3 EXPANSIONS
TABLE 106 TUMOR ABLATION MARKET: EXPANSIONS, JANUARY 2021–MARCH 2024
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats)*
13.1.1 MEDTRONIC PLC
TABLE 107 MEDTRONIC PLC: COMPANY OVERVIEW
FIGURE 45 MEDTRONIC PLC: COMPANY SNAPSHOT (2023)
TABLE 108 MEDTRONIC PLC: PRODUCTS OFFERED
TABLE 109 MEDTRONIC PLC: PRODUCT APPROVALS
13.1.2 JOHNSON & JOHNSON MEDTECH (ETHICON)
TABLE 110 JOHNSON & JOHNSON MEDTECH: COMPANY OVERVIEW
FIGURE 46 JOHNSON & JOHNSON MEDTECH: COMPANY SNAPSHOT (2022)
TABLE 111 JOHNSON & JOHNSON MEDTECH: PRODUCTS OFFERED
13.1.3 STRYKER CORPORATION
TABLE 112 STRYKER CORPORATION: COMPANY OVERVIEW
FIGURE 47 STRYKER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 113 STRYKER CORPORATION: PRODUCTS OFFERED
TABLE 114 STRYKER CORPORATION: PRODUCT APPROVALS
TABLE 115 STRYKER CORPORATION: EXPANSIONS
13.1.4 VARIAN MEDICAL SYSTEMS, INC.
TABLE 116 VARIAN MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW
FIGURE 48 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2023)
TABLE 117 VARIAN MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED
TABLE 118 VARIAN MEDICAL SYSTEMS, INC.: PRODUCT LAUNCHES
TABLE 119 VARIAN MEDICAL SYSTEMS, INC.: DEALS
13.1.5 ANGIODYNAMICS, INC.
TABLE 120 ANGIODYNAMICS, INC.: COMPANY OVERVIEW
FIGURE 49 ANGIODYNAMICS, INC.: COMPANY SNAPSHOT (2023)
TABLE 121 ANGIODYNAMICS, INC.: PRODUCTS OFFERED
TABLE 122 ANGIODYNAMICS, INC.: DEALS
13.1.6 BOSTON SCIENTIFIC CORPORATION
TABLE 123 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
FIGURE 50 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 124 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
13.1.7 EDAP TMS S.A.
TABLE 125 EDAP TMS S.A.: COMPANY OVERVIEW
FIGURE 51 EDAP TMS S.A.: COMPANY SNAPSHOT (2023)
TABLE 126 EDAP TMS S.A.: PRODUCTS OFFERED
13.1.8 MERMAID MEDICAL
TABLE 127 MERMAID MEDICAL: COMPANY OVERVIEW
TABLE 128 MERMAID MEDICAL: PRODUCTS OFFERED
13.1.9 CANYON MEDICAL INC.
TABLE 129 CANYON MEDICAL INC.: COMPANY OVERVIEW
TABLE 130 CANYON MEDICAL INC.: PRODUCTS OFFERED
13.1.10 OLYMPUS CORPORATION
TABLE 131 OLYMPUS CORPORATION: COMPANY OVERVIEW
FIGURE 52 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 132 OLYMPUS CORPORATION: PRODUCTS OFFERED
TABLE 133 OLYMPUS CORPORATION: PRODUCT LAUNCHES
13.1.11 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.
TABLE 134 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
TABLE 135 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
13.1.12 MERIT MEDICAL SYSTEMS, INC.
TABLE 136 MERIT MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW
FIGURE 53 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022)
TABLE 137 MERIT MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED
13.1.13 BIOVENTUS INC.
TABLE 138 BIOVENTUS INC.: COMPANY OVERVIEW
FIGURE 54 BIOVENTUS INC.: COMPANY SNAPSHOT (2023)
TABLE 139 BIOVENTUS INC.: PRODUCTS OFFERED
TABLE 140 BIOVENTUS INC.: DEALS
13.1.14 ICECURE MEDICAL LTD.
TABLE 141 ICECURE MEDICAL LTD.: COMPANY OVERVIEW
FIGURE 55 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023)
TABLE 142 ICECURE MEDICAL LTD.: PRODUCTS OFFERED
TABLE 143 ICECURE MEDICAL LTD.: PRODUCT APPROVALS
TABLE 144 ICECURE MEDICAL LTD.: DEALS
13.1.15 CONMED CORPORATION
TABLE 145 CONMED CORPORATION: COMPANY OVERVIEW
FIGURE 56 CONMED CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 146 CONMED CORPORATION: PRODUCTS OFFERED
13.2 OTHER PLAYERS
13.2.1 MONTERIS MEDICAL
13.2.2 MIANYANG SONIC ELECTRONIC
13.2.3 RF MEDICAL
13.2.4 MINIMAX MEDICAL HOLDING GROUP
13.2.5 SONABLATE
13.2.6 ECO MEDICAL TECHNOLOGY (NANJING) CO., LTD.
13.2.7 STARMED CO., LTD.
13.2.8 SURGNOVA
13.2.9 CREO MEDICAL
13.2.10 MEDSPHERE SHANGHAI
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
